You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Prevention Strategies Reviewed for Women With Migraines

  • Authors: News Author: Laurie Barclay, MD
    CME Author:
    Désirée Lie, MD, MSEd
  • CME / CE Released: 9/6/2006
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 9/6/2007
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, neurologists, gynecologists, and other specialists who care for patients with migraine, particularly women.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  • List general management strategies for migraine management.
  • Describe strategies for migraine prevention in women.


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Laurie Barclay, MD

    Laurie Barclay is a freelance reviewer and writer for Medscape.

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

CME Author(s)

  • Desiree Lie, MD, MSEd

    Clinical Professor of Family Medicine; Director, Division of Faculty Development, University of California, Irvine School of Medicine, Irvine, California

    Disclosures

    Desiree Lie, MD, MSEd, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 200 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/06. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity. AAFP credit is subject to change based on topic selection throughout the accreditation year.


    AAFP Accreditation Questions

    Contact This Provider

    For Nurses

  • This Activity is sponsored by Medscape Continuing Education Provider Unit.

    Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

    Approved for 0.3 contact hour(s) of continuing education for RNs and NPs; 0.3 contact hours are in the area of pharmacology.

    Provider Number: 6FDKKC-PRV-05

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME / CE

Prevention Strategies Reviewed for Women With Migraines

Authors: News Author: Laurie Barclay, MD CME Author: Désirée Lie, MD, MSEdFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / CE Released: 9/6/2006

Valid for credit through: 9/6/2007

processing....

September 6, 2006 — The best prevention strategies for women with migraines are reviewed in an article published in the August issue of the Mayo Clinic Proceedings. The authors emphasize specific migraine prevention strategies for each stage of a woman's life.

"The predominance of this disorder in reproductive-age women and its associated social, functional, and economic consequences make migraine management an important issue in women's health," write Beverly S. Tozer, MD, from the Mayo Clinic College of Medicine in Scottsdale, Arizona, and colleagues. "As women progress through the life stages, the hormonal milieu has a substantial effect on migraine. Menstruation, pregnancy, oral contraception, menopause, and hormone therapy influence its incidence and management."

Migraine is common in women, occurring more frequently than diabetes mellitus, osteoarthritis, or asthma, and affecting 27% of women of reproductive age. One-year migraine prevalence is 18% in females vs 6% in males older than 12 years. A thorough understanding of hormonal influences is critical for optimal management of migraine. Although migraine affects many women throughout their life span, only 3% to 5% of them receive preventive therapy.

The US Headache Consortium has specified situations that warrant preventive treatment of patients with migraine. These include recurring migraines that interfere significantly with daily activities despite acute treatment (eg, >= 2 attacks per month causing disability lasting >= 3 days); frequent headaches (>= 2 per week); contraindication to, failure of, or overuse of acute therapies; adverse events, resulting from acute therapies; patient preference for preventive vs abortive therapies; and uncommon migraine conditions that could lead to neurologic damage, including hemiplegic migraine, basilar migraine, migraine with prolonged aura, or migrainous infarction.

The mainstay of preventive treatment should always include nonpharmacologic strategies. Patients should avoid migraine triggers, especially too much or too little sleep, alcohol, caffeine, and fasting or skipping meals. They should follow a healthy lifestyle including good nutrition, regular sleep, and exercise, and they should use nonpharmacologic techniques to reduce migraine, such as relaxation and biofeedback.

Preventive medications should be taken regularly to reduce the frequency, duration, and severity of anticipated attacks; to reduce the need for abortive medication; and to optimize ability to function. Several well-designed trials have confirmed the efficacy of some treatments, and the US Headache Consortium has recommended other treatments in the absence of relevant randomized controlled trials.

These include beta-blockers (propranolol, timolol, atenolol, metoprolol, nadolol); tricyclic antidepressants (amitriptyline, nortriptyline, protriptyline, doxepin); calcium channel blockers (verapamil); selective serotonin reuptake inhibitors (paroxetine, fluoxetine); neuromodulators (divalproex sodium, valproic acid, gabapentin, topiramate); nonsteroidal anti-inflammatory drugs (NSAIDs) mainly for menstrual migraine; and miscellaneous agents (lisinopril, magnesium, vitamin B 2, feverfew, and botulinum toxin type A injections).

The authors offer specific strategies for prevention of migraine during menstruation, pregnancy, menopause, late life, and with use of oral contraceptives (OCs).

Miniprophylaxis for menstrual migraine may involve use of naproxen sodium, magnesium, ergotamine tartrate plus caffeine, frovatriptan, naritriptan, or sumatriptan. For long-term prevention, standard preventive medications may be used daily, with increased long-term medication dose perimenstrually if needed. Hormonal manipulation may include extended-cycle use of combined OCs, preferably monophasic, low-dose ethinyl estradiol (EE); or add-back estrogen therapy during the placebo week of combined OCs.

"When selecting preventive therapies, physicians should consider the evidence-based efficacy of the agent, medications used previously, patient preference (eg, weight loss or gain, sedation), cost of the drug, and potential therapeutic opportunities to treat migraine and comorbid conditions with a single drug (eg, hypertension and migraine treated with a β-blocker)," the authors write. "All medications should be initiated at a low dose and increased slowly until the effective or maximum dose is achieved or intolerable adverse effects develop. Each treatment option should be given a full therapeutic trial of 2 to 6 months."

Although at least a 50% reduction in the frequency of headaches may often occur with 4 weeks of treatment, the full effect may not be realized for 3 months. Approximately half of patients do not respond adequately to the initial preventive medication. Diary monitoring of frequency, severity, and duration of migraine attacks during treatment will help evaluate the efficacy of the preventive regimen.

"A combined approach using acute and preventive treatment increases the likelihood of long-term benefit," the authors note. "Preventive treatment may reduce the incidence of and vulnerability to attacks, and acute treatment aids in reducing migraine-related disability during attacks."

An important caveat is not to overuse combination analgesics, opioids, ergot alkaloids, and/or triptans for acute migraine attacks, as these may cause medication overuse headaches. During periods of symptomatic treatment abuse, the benefit of preventive medications can be abolished, but the benefit can be regained when medication abuse is successfully terminated. To avoid overuse of acute treatment, clinicians should strictly limit its use to an average of no more than 9 days per month.

"With a decrease in the need for acute treatment, preventive medications greatly decrease the incidence of medication-overuse headaches," the authors conclude. "Preventive medications can effectively reduce resource utilization by decreasing the use of other migraine medications, the use of diagnostic tests, and visits to physician offices and emergency departments. An understanding of the treatment options available for migraine prevention in women at various life stages can help physicians select appropriate prophylactic therapy."

Mayo Clin Proc. 2006;81:1086-1092.